EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial

Changxing Li, Kang Zeng, Dongyuan Zhu, Zhengfu Fan iD, Yong Chen iD, Yu Chen, Yong Li, Mingkai Ji, Ping Duan, Juan Su, Jilong Yang, Yang Tang und 11 weitere

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261456684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 04.08.2026. Verfasst von Changxing Li und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Henlius Biotech, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous squamous cell carcinoma (CSCC) accounts for 20% of all cutaneous cancers. Systemic treatment options for advanced CSCC (aCSCC) include immunotherapy, chemotherapy, and epidermal growth factor receptor (EGFR)-targeted therapy, although their efficacy is limited. HLX07 is a novel anti-EGFR antibody that showed preliminary anti-cancer activity and tolerability in phase I studies.

Objectives

To evaluate the efficacy and safety of HLX07 in patients with aCSCC.

Design

This is a multicenter, open-label, two-part phase II study. In Part 1, patients with metastatic or locally aCSCC not amenable to surgery or curative radiotherapy received 1500 mg (group A) or 1000 mg (group B) HLX07 intravenously every 3 weeks. In Part 2, patients received HLX07 at dose level determined with Part 1 results.

Methods

The primary endpoint was objective response rate (ORR) assessed by an independent radiology review committee (IRRC). Secondary endpoints included other efficacy endpoints, safety, pharmacokinetics, immunogenicity, and quality of life.

Results

Here we focus on Part 1 data. As of April 30, 2024, 31 patients were enrolled (group A, 21; group B, 10). Most patients had metastatic disease (85.7%; 90.0%). Per IRRC assessments, ORR was 19.0% (95% confidence interval (CI), 5.5–41.9) for group A and 60.0% (26.2–87.8) for group B; median progression-free survival was 4.9 (95% CI, 1.4–6.5) and 7.9 (95% CI, 2.2–11.1) months, and median duration of response was 5.0 (95% CI, 2.9–not evaluable (NE)) and 7.4 (95% CI, 2.8–NE) months, respectively. Median overall survival was 11.8 months (95% CI, 5.9–NE) and not reached (95% CI, 2.2–NE). Grade ⩾3 treatment-related adverse events (TRAEs) occurred in 8 (38.1%) and 3 (30.0%) patients, respectively. No TRAE leading to death or treatment discontinuation was reported.

Conclusion

HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.

Trial registration

ClinicalTrials.gov NCT05238363.

Schlagwörter

Stichwörter der Autor:innen

EGFR-targeted therapyHLX07cetuximabclinical trialcutaneous squamous cell carcinomapanitumumab

Autor:innen und Institutionen

  • Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Dermatology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China.
  • Department of Dermatology, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Baiyun District, Guangzhou, Guangdong 510000, China.
  • Department of Rare Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Bone and Soft Tissue Oncology, Beijing Cancer Hospital, Beijing, China.
  • Department of Bone and Soft Tissue Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Zhengfu Fan, Yong Chen

Förderung

  • Shanghai Henlius Biotech, Inc.

Zitieren

APA

Li, C., Zeng, K., Zhu, D., Fan, Z., Chen, Y., Chen, Y., Li, Y., Ji, M., Duan, P., Su, J., Yang, J., Tang, Y., Zhang, M., Wang, S., Yu, G., Huang, Y., Chen, R., Hu, X., Yang, F., …, & Zhu, J. (2026). HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261456684

Vancouver

Li C, Zeng K, Zhu D, Fan Z, Chen Y, Chen Y, et al. HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261456684

BibTeX
@article{Li2026,
  author = {Li, Changxing and Zeng, Kang and Zhu, Dongyuan and Fan, Zhengfu and Chen, Yong and Chen, Yu and Li, Yong and Ji, Mingkai and Duan, Ping and Su, Juan and Yang, Jilong and Tang, Yang and Zhang, Mingjun and Wang, Siyang and Yu, Gengsheng and Huang, Yisheng and Chen, Rongyi and Hu, Xuhui and Yang, Futang and Yu, Haoyu and Wang, Qingyu and Li, Jing and Zhu, Jun},
  title = {HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261456684}
}
Kostenlos starten →